As of Apr 24
| -0.13 / -2.06%|
The 7 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 9.00, with a high estimate of 21.00 and a low estimate of 6.00. The median estimate represents a +45.87% increase from the last price of 6.17.
The current consensus among 8 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.